Bisphosphonates may reduce short-term pain in complex regional pain syndrome
1. In this systematic review and meta-analysis, bisphosphonates may reduce short-term (> 4 weeks to 3 months) pain in complex ...
Tag: bisphosphonates
Denosumab may increase risk of major adverse cardiovascular events but reduce fracture risk in patients receiving dialysis
1. In this target trial emulation study, denosumab was associated with an increased risk of major adverse cardiovascular events compared ...
Denosumab increases risk of severe hypocalcemia in women with osteoporosis and chronic kidney disease
1. In this target trial emulation study, denosumab was found to increase the risk of hypocalcemia requiring emergency treatment as ...
Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
1. Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab use are associated with reduced clinical fractures in postmenopausal patients with osteoporosis. 2. ...
Osteoporosis medications may improve bone health in men receiving androgen deprivation therapy for prostate cancer
1. Bisphosphonates and denosumab increased bone mineral density (BMD) in men receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer, ...
Bisphosphonates may reduce risk of endometrial cancer
1. In a prospective cohort study of over 89 000 postmenopausal women, the use of bisphosphonates for osteoporosis was associated ...
![Statin therapy does not prevent osteoporotic fractures [JUPITER trial]](https://www.2minutemedicine.com/wp-content/uploads/2014/12/osteoporosis-e1417474828821-350x250.jpg)
Zoledronic acid may increase bone density in frail elderly women
1. A single dose of zoledronic acid improved bone mineral density over 2 years in frail elderly women. 2. Rates ...
Key drugs reduce fracture risk in osteoporosis
1. This systematic review demonstrated that in postmenopausal women with osteoporosis, bisphosphonates, denosumab and teriparatide were associated with a significantly ...
